PRESS RELEASES

Date Title and Summary View
Jun 8, 2009
Summary ToggleGroundbreaking Approach to Treating Obesity Highlighted by Keynote Lecture at American Diabetes Association Annual Scientific Sessions

Zafgen Scientific Advisory Board Member and Pioneering Researcher Dr. Randy J. Seeley Underscores the Active Role of Adipose Vasculature in Metabolic Disease

Summary ToggleGroundbreaking Approach to Treating Obesity Highlighted by Keynote Lecture at American Diabetes Association Annual Scientific Sessions
May 14, 2009
Summary ToggleZafgen, Inc. Announces Participation at BIO 2009 International Convention Summary ToggleZafgen, Inc. Announces Participation at BIO 2009 International Convention
May 5, 2009
Summary ToggleZafgen, Inc. Appoints Matthias Jaffe to Chief Financial Officer and Vice President of Business Development

Industry Executive Brings Extensive Experience to Novel Obesity Therapeutics Company

Summary ToggleZafgen, Inc. Appoints Matthias Jaffe to Chief Financial Officer and Vice President of Business Development
Apr 27, 2009
Summary ToggleZafgen, Inc. to Present at Xconomy Forum Summary ToggleZafgen, Inc. to Present at Xconomy Forum
Mar 25, 2009
Summary ToggleZafgen, Inc. to Present at Upcoming Conferences Summary ToggleZafgen, Inc. to Present at Upcoming Conferences
Jan 29, 2009
Summary ToggleArgenta Discovery and Zafgen Announce Contract Drug Discovery Collaboration in Obesity Summary ToggleArgenta Discovery and Zafgen Announce Contract Drug Discovery Collaboration in Obesity
Oct 16, 2008
Summary ToggleZafgen Inc. to Present at First Annual Boston Biotech R&D Conference Summary ToggleZafgen Inc. to Present at First Annual Boston Biotech R&D Conference
Sep 9, 2008
Summary ToggleZafgen Inc. Appoints Industry Veteran and Recognized Metabolic Disorders Expert Thomas Hughes, Ph.D., as Company’s First Chief Executive Officer

Former Head of Diabetes Research at Novartis Will Lead Company in Development of Novel Therapies to Treat Obesity

Summary ToggleZafgen Inc. Appoints Industry Veteran and Recognized Metabolic Disorders Expert Thomas Hughes, Ph.D., as Company’s First Chief Executive Officer